AbbVie‘s (ABBV) two-decade Humira monopoly came to an end Tuesday after Amgen (AMGN) launched its biosimilar knockoff at a 55% discount to the original. But AbbVie stock advanced. X The biosimil...
Tag: Humira
Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth
Credit Suisse has initiated coverage on AbbVie Inc (NYSE: ABBV) with an Outperform rating and a price target of $170. AbbVie stands on the edge of best-selling Humira’s U.S. loss of exclusivity (LOE) ...
Ups & Downs: Top Pharmaceutical Stocks Post-COVID
Who will be Big Pharma’s winners post-COVID? Getty Images There’s little argument that the COVID-19 pandemic reshaped the world. While families and governments continue to grapple with Omicron v...
AbbVie’s stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humira
An earlier version of this report referred to Humana in the headline, not Humira. It has been corrected. Shares of AbbVie Inc. ABBV, +0.08% gained 1.4% in premarket trading on Wednesday after the comp...